You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePuromycin
Accession NumberDB08437
TypeSmall Molecule
GroupsExperimental
DescriptionPuromycin is an antibiotic that is a protein synthesis inhibitor by inhibiting translation. Puromycin is used in cell biology as selective agent in cell culture systems. It is toxic to prokaryotic and eukaryotic cells.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4A6ZS6Q2CL
CAS number53-79-2
WeightAverage: 471.5096
Monoisotopic: 471.223017073
Chemical FormulaC22H29N7O5
InChI KeyInChIKey=RXWNCPJZOCPEPQ-NVWDDTSBSA-N
InChI
InChI=1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1
IUPAC Name
(2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)-9H-purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide
SMILES
[H][C@](N)(CC1=CC=C(OC)C=C1)C(=O)N[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(N2C=NC3=C(N=CN=C23)N(C)C)[C@]1([H])O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • 6-alkylaminopurine
  • N-glycosyl compound
  • Glycosyl compound
  • Phenylpropylamine
  • Amphetamine or derivatives
  • 6-aminopurine
  • Purine
  • Imidazopyrimidine
  • Methoxybenzene
  • Dialkylarylamine
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Aminopyrimidine
  • Alkyl aryl ether
  • Fatty acyl
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • N-substituted imidazole
  • Monosaccharide
  • Fatty amide
  • Saccharide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Oxolane
  • Imidazole
  • Azole
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier-0.8691
Caco-2 permeable-0.7728
P-glycoprotein substrateSubstrate0.737
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9243
CYP450 2C9 substrateNon-substrate0.8029
CYP450 2D6 substrateNon-substrate0.8107
CYP450 3A4 substrateSubstrate0.7097
CYP450 1A2 substrateNon-inhibitor0.9058
CYP450 2C9 inhibitorNon-inhibitor0.9133
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9393
CYP450 3A4 inhibitorNon-inhibitor0.724
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8922
Ames testNon AMES toxic0.8607
CarcinogenicityNon-carcinogens0.8681
BiodegradationNot ready biodegradable0.9882
Rat acute toxicity2.2651 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9903
hERG inhibition (predictor II)Non-inhibitor0.5719
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point168°C-182°Chttp://www.fermentek.co.il/puromycin.htm
water solubility50mg/mlhttp://www.fermentek.co.il/puromycin.htm
Predicted Properties
PropertyValueSource
Water Solubility1.01 mg/mLALOGPS
logP-0.1ALOGPS
logP-0.3ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)12.35ChemAxon
pKa (Strongest Basic)8.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area160.88 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity122.96 m3·mol-1ChemAxon
Polarizability49.46 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-03di-0900300000-347a5da10b8c2c85e6c0View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-03dj-0900000000-4a2ce92d6902f4ad8eaaView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-03dj-1900000000-039465e4b89c78bd0b11View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0229-0520900000-37dea53aac093ce884f6View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-03di-0910100000-f60802f57acd3074b4c1View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-03xs-1900000000-d2fbe55b0731a8cf001fView in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AceclofenacAceclofenac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Puromycin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Puromycin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
AdapaleneAdapalene may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Alendronic acidPuromycin may increase the hypocalcemic activities of Alendronic acid.
AmdinocillinThe serum concentration of Puromycin can be decreased when it is combined with Amdinocillin.
AmoxicillinThe serum concentration of Puromycin can be decreased when it is combined with Amoxicillin.
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Puromycin.
AmpicillinThe serum concentration of Puromycin can be decreased when it is combined with Ampicillin.
AntipyrineAntipyrine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
ApremilastApremilast may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
AzapropazoneAzapropazone may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
AzelastineAzelastine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
AzlocillinThe serum concentration of Puromycin can be decreased when it is combined with Azlocillin.
BalsalazideBalsalazide may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
BenoxaprofenBenoxaprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Benzathine benzylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Benzathine benzylpenicillin.
BenzylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Benzylpenicillin.
Benzylpenicillin PotassiumThe serum concentration of Puromycin can be decreased when it is combined with Benzylpenicillin Potassium.
BevacizumabBevacizumab may increase the cardiotoxic activities of Puromycin.
Botulinum Toxin Type APuromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.
Botulinum Toxin Type BPuromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.
BromfenacBromfenac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Puromycin.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Puromycin.
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Puromycin.
CarbenicillinThe serum concentration of Puromycin can be decreased when it is combined with Carbenicillin.
CarboplatinPuromycin may increase the ototoxic activities of Carboplatin.
CarprofenCarprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
CastanospermineCastanospermine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
CelecoxibCelecoxib may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
ChloroquineChloroquine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
CisplatinCisplatin may increase the nephrotoxic activities of Puromycin.
ClodronatePuromycin may increase the hypocalcemic activities of Clodronate.
ClonixinClonixin may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
CloxacillinThe serum concentration of Puromycin can be decreased when it is combined with Cloxacillin.
ColistimethatePuromycin may increase the nephrotoxic activities of Colistimethate.
CyclacillinThe serum concentration of Puromycin can be decreased when it is combined with Cyclacillin.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Puromycin.
CyclosporinePuromycin may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneD-Limonene may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Puromycin.
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Puromycin.
DiclofenacDiclofenac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
DicloxacillinThe serum concentration of Puromycin can be decreased when it is combined with Dicloxacillin.
DiflunisalDiflunisal may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Puromycin.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Puromycin.
DigoxinDigoxin may decrease the cardiotoxic activities of Puromycin.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Puromycin.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Puromycin.
DroxicamDroxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
EpirizoleEpirizole may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Puromycin.
EtanerceptEtanercept may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Etidronic acidPuromycin may increase the hypocalcemic activities of Etidronic acid.
EtodolacEtodolac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
EtofenamateEtofenamate may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
EtoricoxibEtoricoxib may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Evening primrose oilEvening primrose oil may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
exisulindexisulind may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
FenbufenFenbufen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
FenoprofenFenoprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
FloctafenineFloctafenine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
FlucloxacillinThe serum concentration of Puromycin can be decreased when it is combined with Flucloxacillin.
FlunixinFlunixin may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
FlurbiprofenFlurbiprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
FoscarnetFoscarnet may increase the nephrotoxic activities of Puromycin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Puromycin.
HMPL-004HMPL-004 may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
IbandronatePuromycin may increase the hypocalcemic activities of Ibandronate.
IbuprofenIbuprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
IbuproxamIbuproxam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
IcatibantIcatibant may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
IndomethacinIndomethacin may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
IndoprofenIndoprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
IsoxicamIsoxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneKebuzone may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
KetoprofenKetoprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacKetorolac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
LeflunomideLeflunomide may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
LornoxicamLornoxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
LoxoprofenLoxoprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
LumiracoxibLumiracoxib may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
MannitolMannitol may increase the nephrotoxic activities of Puromycin.
MasoprocolMasoprocol may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
MecamylaminePuromycin may increase the neuromuscular blocking activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Mefenamic acidMefenamic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
MeloxicamMeloxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
MesalazineMesalazine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
MetamizoleMetamizole may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
MeticillinThe serum concentration of Puromycin can be decreased when it is combined with Meticillin.
MezlocillinThe serum concentration of Puromycin can be decreased when it is combined with Mezlocillin.
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
NabumetoneNabumetone may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
NafcillinThe serum concentration of Puromycin can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
NaproxenNaproxen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
NCX 4016NCX 4016 may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacNepafenac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidNiflumic Acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
NimesulideNimesulide may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
OlopatadineOlopatadine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
OlsalazineOlsalazine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
OrgoteinOrgotein may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
OuabainOuabain may decrease the cardiotoxic activities of Puromycin.
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Puromycin.
OxacillinThe serum concentration of Puromycin can be decreased when it is combined with Oxacillin.
OxaprozinOxaprozin may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Puromycin.
PamidronatePuromycin may increase the hypocalcemic activities of Pamidronate.
ParecoxibParecoxib may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PhenoxymethylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Phenoxymethylpenicillin.
PhenylbutazonePhenylbutazone may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PimecrolimusPimecrolimus may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PiperacillinThe serum concentration of Puromycin can be decreased when it is combined with Piperacillin.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Puromycin.
PirfenidonePirfenidone may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PiroxicamPiroxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PivampicillinThe serum concentration of Puromycin can be decreased when it is combined with Pivampicillin.
PivmecillinamThe serum concentration of Puromycin can be decreased when it is combined with Pivmecillinam.
Procaine benzylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Procaine benzylpenicillin.
PropacetamolPropacetamol may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PTC299PTC299 may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
ResveratrolResveratrol may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronatePuromycin may increase the hypocalcemic activities of Risedronate.
RofecoxibRofecoxib may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
SalicylamideSalicylamide may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Salicylic acidSalicylic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
SalsalateSalsalate may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
SeratrodastSeratrodast may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
SRT501SRT501 may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
SulbactamThe serum concentration of Puromycin can be decreased when it is combined with Sulbactam.
SulfasalazineSulfasalazine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
SulindacSulindac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
SuprofenSuprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Technetium Tc-99m MedronatePuromycin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.
TenofovirThe serum concentration of Puromycin can be increased when it is combined with Tenofovir.
TenoxicamTenoxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
TepoxalinTepoxalin may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
TeriflunomideTeriflunomide may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
TicarcillinThe serum concentration of Puromycin can be decreased when it is combined with Ticarcillin.
TiludronatePuromycin may increase the hypocalcemic activities of Tiludronate.
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
TolmetinTolmetin may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Puromycin.
TranilastTranilast may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Puromycin.
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
ValdecoxibValdecoxib may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
VancomycinVancomycin may increase the nephrotoxic activities of Puromycin.
ZaltoprofenZaltoprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
ZileutonZileuton may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Zoledronic acidPuromycin may increase the hypocalcemic activities of Zoledronic acid.
ZomepiracZomepirac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
May play a role in compensating for the inactivated X-linked gene during spermatogenesis.
Gene Name:
RPL10L
Uniprot ID:
Q96L21
Molecular Weight:
24518.595 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Associated with ribosomes but is not required for canonical ribosome function and has extra-ribosomal functions. Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes. Upon interferon-gamma activation and subsequent phosphorylation dissociates from the ribo...
Gene Name:
RPL13A
Uniprot ID:
P40429
Molecular Weight:
23577.11 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL23
Uniprot ID:
P62829
Molecular Weight:
14865.335 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL15
Uniprot ID:
P61313
Molecular Weight:
24145.945 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL19
Uniprot ID:
P84098
Molecular Weight:
23465.775 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
This protein binds to a specific region on the 26S rRNA.
Gene Name:
RPL23A
Uniprot ID:
P62750
Molecular Weight:
17694.885 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Involved in the biogenesis of the 60S ribosomal subunit. Ensures the docking of GTPBP4/NOG1 to pre-60S particles (By similarity).
Gene Name:
RSL24D1
Uniprot ID:
Q9UHA3
Molecular Weight:
19621.02 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL26L1
Uniprot ID:
Q9UNX3
Molecular Weight:
17256.2 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Not Available
Gene Name:
RPL8
Uniprot ID:
P62917
Molecular Weight:
28024.52 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Binds to the 23S rRNA.
Gene Name:
RPL37
Uniprot ID:
P61927
Molecular Weight:
11077.81 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
The L3 protein is a component of the large subunit of cytoplasmic ribosomes.
Gene Name:
RPL3
Uniprot ID:
P39023
Molecular Weight:
46108.72 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Structural constituent of ribosome
Specific Function:
Binds to 5S ribosomal RNA (By similarity). Required for rRNA maturation and formation of the 60S ribosomal subunits. Promotes nucleolar location of PML (By similarity).
Gene Name:
RPL11
Uniprot ID:
P62913
Molecular Weight:
20252.235 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
unknown
General Function:
Transferase activity, transferring amino-acyl groups
Specific Function:
Functions in the N-end rule pathway of protein degradation where it conjugates Leu, Phe and, less efficiently, Met from aminoacyl-tRNAs to the N-termini of proteins containing an N-terminal arginine or lysine.
Gene Name:
aat
Uniprot ID:
P0A8P1
Molecular Weight:
26618.275 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 15, 2010 15:31 / Updated on August 17, 2016 12:24